Please type a plus sign (+) inside this box → Under (ne Paperwork Reduction Act of 1995, no persons are required to re-	Approved Patent and Trademark O espond to a collection of information unle	ffic and S. DEPARTMENT OF COMMERCE		
Supstitute for form 1449A/PTO	Complete if Known			
FEB 1 5 2002	Application Number	09/826716		
FORMATION DISCLOSURE	Filing Date	04/05/2001		
STATEMENT BY APPLICANT	First Named Inventor	Karpusas, Michael		
CATA TRIND	Group Art Unit	1754		

2

(use as many sheets as necessary)

of

Sheet

U.S. PATENT DOCUMENTS						
Examiner Cit Initials No	Cito	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,
	No.1		Number	Kind Code ² (<i>if known</i>)	of Cited Document	Cited Document MM-DD-YYYY
				· · · · · · · · · · · · · · · · · · ·		
					·	
					 	···
		*				
						P/
						"CC~
						FR
						200
						- C 1 - COD
			<u> </u>			
						· · · · · · · · · · · · · · · · · · ·
$\neg \neg$	1					

Examiner Name

Attorney Docket Number

Not assigned

A062 US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Doo	Cument Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
rus	AA		WO 01/73444	A2	Cambridge Univ. Tech. Serv	10/4/01		
			<u>-</u> .					

Examiner Signature Date Considered 09/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

→

PTC/SB/08B (10-96)
Approved for through 10/31/99. OMB 0651-0031
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office. U.S. DEPARTMENT OF COMMERC e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Application Number
 09/826716

 Filing Date
 04/05/2001

 First Named Inventor
 Karpusas, Michael

 Group Art Unit
 1754

 Examiner Name
 Not essigned

Complete if Known


(use as many sheets as necessary)
Sheet 2 of 2.

Examiner Name Not assigned
Attorney Docket Number A062 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No.1 publisher, city and/or country where published. Baldwin, Eric et al., 1998, Chemical Abstracts XP-002132455, 6:7:923-925, "Cation binding to the integrin BΑ CD11 I domain and activation" Gotwals, Philip et al., 1996, J. Clin. Invest., 97:2469-2477, "The alpha1 beta1 Integrin Is Expressed during BB Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization" Nolte, Matthais et al., 1999, Federation of European Biochemical Societies, 452:3:379-385, "Crystal structure of the alphalbetal integrin I-domain: insights into integrin I-domain function" Qu, Aidong et al., 1995, Proc. Natl Acad. Sci., XP-002132453, 92:10277-10281, "Crystal structure of the BD I-domain from the CD11a/CD18 (LFA-1, alphaLBeta2 integrin" Salminen T.A. et al., 1999, Chemical Abstracts XP-002132454, 131:239407, "Production, crystallization UD and preliminary X-rays analysis of the human integrin alpha1 I-domain" TEB 25 NOTER

Examiner	1,0	Date	00/10-
Signature	Mmb	Considered	678/03

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.